Drug Trial Radar · NCT00505778
A Comparison of Once a Day Dose Compared to 2 Doses/Day
Last checked: Nov 19, 2026Latest source record: Apr 22, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,027
Actual
Start
Jul 2007
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Warner ChilcottIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
Conditions
- Ulcerative Colitis
Interventions
Mesalamine Once-DailyDrug
Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
Mesalamine Twice-DailyDrug
Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI)Time frame: 6 months
Locations
245 sites in 3 countries. Site status is shown where the registry gives one.
Research Facility
Athens, Alabama
Research Facility
Birmingham, Alabama
Research Facility
Birmingham, Alabama
Research Facility
Dothan, Alabama
Research Facility
Phoenix, Arizona
Research Facility
Scottsdale, Arizona
Research Facility
Tucson, Arizona
Research Facility
Tuscon, Arizona
Research Facility
Little Rock, Arkansas
Research Facility
Lowell, Arkansas
Research Facility
Anaheim, California
Research Facility
Beverly Hills, California
Research Facility
Chico, California
Research Facility
Encinitas, California
Research Facility
Folsom, California
Research Facility
La Mesa, California
Research Facility
Lancaster, California
Research Facility
Long Beach, California
Research Facility
Los Angeles, California
Research Facility
Los Angeles, California
Research Facility
Madera, California
Research Facility
Merced, California
Research Facility
Mission Hills, California
Research Facility
Monterey, California
Research Facility
Murrieta, California
Research Facility
Oakland, California
Research Facility
Orange, California
Research Facility
Palm Springs, California
Research Facility
San Carlos, California
Research Facility
San Diego, California
Research Facility
San Diego, California
Research Facility
San Diego, California
Research Facility
San Francisco, California
Research Facility
San Francisco, California
Research Facility
Torrance, California
Research Facility
Torrance, California
Research Facility
Upland, California
Research Facility
Englewood, Colorado
Research Facility
Golden, Colorado
Research Facility
Lafayette, Colorado
Showing 40 of 245 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.